In addition to our current clinical programs, we’re actively evaluating opportunities to advance our two pipeline products into additional clinical trials. Both ROR1 and the ets-family transcription protein are highly expressed in multiple cancers. We are also investing in R&D to support additional modalities for targeting ROR1 as well as an ongoing research programs at UCSD and Georgetown University. Our academic collaborations further strengthen both of these programs.
We are recruiting patients
- With CLL for a Phase 1 study of Cirmtuzumab, our anti-ROR1 monoclonal antibody
- With Ewing sarcoma for a Phase 1 study of TK216, our small molecule inhibitor of ets-family transcription factor oncoproteins